Therapeutic Products Directorate [ TPD | Therapeutic Products Programme | Drugs and Medical Devices Directorate | Drugs and Medical Devices Programme | Drugs Directorate ]

cabin service director | customer service director | cabin crew manager | chief purser

Therapeutic Products Directorate guidelines

DG Internal Market and Services | Directorate-General for the Internal Market and Services

civil service administrator | public service director | public administration manager | public body administrator

auto shop service manager | motor vehicle repair shop manager | car shop repair service director | garage manager

administrative services manager | administration department manager | administrative manager | administration director | administrative services director | support services manager | administrative services, chief | administrative services supervisor | administration supervisor | office manager | office administrator

From the Department of Health: Dr. Robert Peterson, Director General, Therapeutics Products Directorate, Health Products and Food Branch; David Lee, Director, Office of Patented Medicines and Liaison; Anne Bowes, Manager, Patent and Liaison; David K. Edwards, Legal Counsel, Legal Services.

From the Department of Health: Dr. Robert Peterson, Director General, Therapeutics Products Directorate, Health Products and Food Branch; David Lee, Director, Office of Patented Medicines and Liaison; Anne Bowes, Manager, Patent and Liaison; David K. Edwards, Legal Counsel, Legal Services.

Question No. 609 Ms. Anne Minh-Thu Quach: With respect to drug regulation and approval: (a) does the 2012 Economic Action Plan provide for decreases or increases in the financial and human resources allocated to (i) drug approval services, (ii) regulatory activities to evaluate and monitor the safety, efficacy and quality of drugs before and after they enter the marketplace, (iii) activities related to the review of submissions by drug manufacturers for market authorization and post-market changes, (iv) activities related to enforcing compliance with existing regulations, including those concerning clinical trials, drug manufacturing and ...[+++] the reporting of adverse drug reactions, (v) activities of the Patented Medicine Prices Review Board, (vi) services such as the Patent Register, Drug Product Database, Notice of Compliance, and Progressive Licensing Project, (vii) various areas of Health Canada such as the Marketed Health Products Directorate, Therapeutic Products Directorate, Biologics and Genetic Therapies Directorate, and the Veterinary Drugs Directorate; (b) for each of the programs and directorates listed in (a), (i) what is the estimated extent of the decreases or increases in human or financial resources, (ii) are positions expected to be cut and, if so, how many will be eliminated; (c) was a value-for-money assessment conducted for the drug approval process; and (d) what is the government’s financial allocation plan regarding drug regulation?

Witnesses: From Health Canada: Denis Gauthier, Assistant Deputy Minister, Information, Analysis and Connectivity Branch; Jerry Lee, Director, Infostructure Systems Management Division, Information, Analysis and Connectivity Branch; Mimi Breton, Executive Director, Hepatitis C Division, Health Promotion and Programs Branch; Catherine Stewart, Director, Policy Development and Coordination Division, Health Promotion and Programs Branch; David Fransen, Director general, Population Health Directorate, Health Promotion and Programs Branch; Janet Davies, Director, Strategies and Systems for Health Directorate, Health Promotion and Programs ...[+++] Branch; Joel Weiner, A/Director General, Policy, Planning and Coordination Directorate, Health Protection Branch; Dr. Moe Hussain, A/Director, Branch Planning Bureau, Health Protection Branch; Gérard Séguin, Director, Financial Services, Health Protection Branch; Margaret Hassock, A/Director, Financial Services, Administration Program, Departmental Planning and Financial Administration Corporate Services Branch; Janice L. Pound, Acting Manager, Office of Strategic Planning, Communications and Quality, Therapeutic Products Programme; Paul R. Mayers, Acting Director, Bureau of Microbial Hazards, Food Directorate, Health Protection Branch; Greg Hunter, Director, Information Resource Management Division; Hervé Leblanc, Director, Health Canada.